4.2 Review

The Mycobacterium tuberculosis MEP (2C-methyl-D-erythritol 4-phosphate) pathway as a new drug target

期刊

TUBERCULOSIS
卷 89, 期 1, 页码 1-11

出版社

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.tube.2008.07.004

关键词

Tuberculosis; 2C-methyl-D-erythritol 4-phosphate pathway; High throughput screening campaigns; Anti-infectives

资金

  1. National Institutes of Allergy and Infectious Diseases, NIH [Al-018357, Al-065357]
  2. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018357, U54AI065357, R37AI018357, R01AI018357] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Tuberculosis (TB) is still a major public health problem, compounded by the human immunodeficiency virus (HIV)-TB co-infection and recent emergence of multidrug-resistant (MDR) and extensively drug resistant (XDR)-TB. Novel anti-TB drugs are urgently required. In this context, the W-methyl-D-erythritol 4-phosphate (MEP) pathway of Mycobacterium tuberculosis has drawn attention: it is one of several pathways vital for M. tuberculosis viability and the human host lacks homologous enzymes. Thus, the MEP pathway promises bacterium-specific drug targets and the potential for identification of lead Compounds unencumbered by target-based toxicity. Indeed, fosmidomycin is now known to inhibit the second step in the MEP pathway. This review describes the cardinal features of the main enzymes of the MEP pathway in M. tuberculosis and how these can be manipulated in high throughput screening campaigns in the search for new anti-infectives against TB. (C) 2008 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据